Regeneron Pharmaceuticals (REGN) : Net money flow in Regeneron Pharmaceuticals (REGN) was negative ($3.53 million) and the inflow of money on uptick was $5.26 million, whereas, the outflow of money on downticks amounted to $8.79 million on Tuesday. The traders used every opportunity of price strength in the stock to sell their positions, hence, the total uptick to downtick ratio was 0.6. The block trades show that the large investors, were aggressive sellers in the stock. On the other hand, the total value of block trades done on downticks was $0.1 million. The money flow in block trades was negative ($0). Regeneron Pharmaceuticals (REGN) gained $0.47 cent during the day and reached $399.85, a gain of 0.12% over the previous day.
Also, Baird downgrades its view on Regeneron Pharmaceuticals (NASDAQ:REGN) according to the research report released by the firm to its investors. The shares have now been rated Neutral by the stock experts at the ratings house. Earlier, the shares had a rating of Outperform. The rating by the firm was issued on August 5, 2016.
Regeneron Pharmaceuticals, Inc. has lost 6.04% in the last five trading days and dropped 8.94% in the last 4 weeks. Regeneron Pharmaceuticals, Inc. has dropped 2.25% during the last 3-month period . Year-to-Date the stock performance stands at -27.2%.
Regeneron Pharmaceuticals (NASDAQ:REGN): The stock opened at $398.38 on Tuesday but the bulls could not build on the opening and the stock topped out at $402.36 for the day. The stock traded down to $394.42 during the day, due to lack of any buying support eventually closed down at $395.22 with a loss of -1.04% for the day. The stock had closed at $399.38 on the previous day. The total traded volume was 526,904 shares.
In a related news, Goldstein Joseph L, director of Regeneron Pharmaceuticals Inc, unloaded 2,125 shares at an average price of $425 on July 29, 2016. The total amount of the transaction was worth $903,125, according to the disclosed information with the Securities and Exchange Commission in a Form 4 filing.
Regeneron Pharmaceuticals, Inc. is an integrated biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. The Company commercializes medicines for eye diseases, colorectal cancer, and a rare inflammatory condition and has product candidates under development in other areas, including hypercholesterolemia, oncology, rheumatoid arthritis (RA), asthma and atopic dermatitis. The Companys marketed products include EYLEA (aflibercept) injection, ZALTRAP (ziv-aflibercept) injection for intravenous infusion and ARCALYST (rilonacept) injection for subcutaneous use. The Company has 17 product candidates in clinical development. Its product candidates consist of two trap-based clinical programs and 15 human monoclonal antibody product candidates. The Company has generated each of the antibodies using its VelocImmune technology.